Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Monterrey
Clinical trial register · Mexico

Clinical Trials in Monterrey, 2026

Every study on the ClinicalTrials.gov registry that lists a site in Mexico and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 1580 matching records held by the registry are in this view. Synced 30 Sep 2026, 03:17 UTC
1580
Studies in scope
all four open statuses
714
Recruiting now
open to new participants
249
Lead sponsors
across recruiting studies
Top sites
Mexico City 22 Monterrey 21 Guadalajara 18 Chihuahua City 15 Zapopan 12
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Merck Sharp & Dohme LLC42 AstraZeneca32 Eli Lilly and Company28 Bristol-Myers Squibb21 Hoffmann-La Roche18 Clear sponsor filter
Site location
Mexico City22 Monterrey21 Guadalajara18 Chihuahua City15 Zapopan12
All 31 locations
Target enrolment
to

Trials with a site in Monterrey

21 of 1580 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Sites in Mexico
Start
Not yet open
Long-term Extension Study to Evaluate Safety and Tolerability of Admilparant in Participants With Pulmonary Fibrosis
NCT07441408Pulmonary Fibrosis
DrugAdmilparant
Bristol-Myers Squibb
Phase 3
2,380
Aguascalientes, Chihuahua City, México, Metepec, Guadalajara, Morelia, Monterrey, Oaxaca City
2026-12-16
Recruiting
A Study to Evaluate the Safety, Tolerability, and Efficacy of Pumitamig Alone or in Combination With Other Agents in Participants With Advanced Renal Cell Carcinoma (RCC) (ROSETTA RCC-208)
NCT07293351Advanced Renal Cell Carcinoma (RCC)
DrugsCasdatifan·Pumitamig·Cabozantinib·Yervoy
Bristol-Myers Squibb
Phase 1/2
474
Monterrey, Oaxaca City, Puebla City, Tlalpan
2026-03-26
Recruiting
A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)
NCT07361497Non-small Cell Lung Cancer (NSCLC)
DrugsPumitamig·Durvalumab
Bristol-Myers Squibb
Phase 3
850
Saltillo, Tijuana, Zapopan, Monterrey, Puebla City, Querétaro
2026-03-16
Recruiting
A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202)
NCT07361510Non-Small Cell Lung Cancer (NSCLC)
DrugsPumitamig·Pembrolizumab
Bristol-Myers Squibb
Phase 3
750
Guadalajara, Zapopan, Mexico City, Monterrey, Oaxaca City, Querétaro
2026-03-12
Recruiting
A Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion
NCT07063745Metastatic Non-small Cell Lung Cancer With MTAP Deletion
DrugsNavlimetostat·Nab-paclitaxel·Pemetrexed·Paclitaxel
Bristol-Myers Squibb
Phase 2/3
590
Tijuana, Guadalajara, Zapopan, Mexico City, Monterrey, Oaxaca City, Chihuahua City, Puebla City
2026-01-02
Recruiting
A Study to Evaluate the Efficacy, Safety, and Drug Levels of Deucravacitinib (BMS-986165) in Adolescent Participants With Moderate to Severe Plaque Psoriasis
NCT06979453Plaque Psoriasis
DrugDeucravacitinib
Bristol-Myers Squibb
Phase 3
366
Zapopan, Mexico City, Monterrey, Chihuahua City, Mérida, Toluca, Veracruz
2025-12-03
Recruiting
A Study to Evaluate the Long-term Efficacy and Safety of KarXT + KarX-EC for Agitation in Alzheimer's Disease (ADAGIO-3)
NCT06937229Alzheimer Disease, Agitation
DrugsKarX-EC·KarXT
Bristol-Myers Squibb
Phase 3
650
Saltillo, Guadalajara, Mexico City, Monterrey, San Luis Potosí City, Tlalnepantla
2025-12-02
Active, closed
A Study Comparing Navlimetostat (BMS-986504) in Combination With Nab-paclitaxel and Gemcitabine Versus Placebo in Combination With Nab-paclitaxel and Gemcitabine in Participants With Untreated Metastatic Pancreatic Ductal Adenocarcinoma With Homozygous MTAP Deletion (MountainTAP-30)
NCT07076121Pancreatic Ductal Adenocarcinoma
DrugsNavlimetostat·Abraxane·Nab-paclitaxel·Gemcitabine
Bristol-Myers Squibb
Phase 2/3
470
Zapopan, Cuauhtémoc, Ciudad de México, Mexico City, Monterrey, Oaxaca City, Mérida, Puebla City, Querétaro
2025-10-23
Recruiting
Long-Term Safety Study of Deucravacitinib Versus Ustekinumab in Participants With Psoriasis (PRAGMATYK)
NCT07116967Plaque Psoriasis
DrugsUstekinumab·Deucravacitinib
Bristol-Myers Squibb
Phase 3
3,040
Mexicali, Guadalajara, Zapopan, Monterrey, Mérida, Chihuahua City, Mexico City
2025-09-22
Recruiting
A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)
NCT06926868Breast Neoplasms
DrugsIza-bren·Nab-paclitaxel·Capecitabine·Gemcitabine
Bristol-Myers Squibb
Phase 2/3
600
Mexico City, Tijuana, Guadalajara, Monterrey, Oaxaca City, Mérida, Chihuahua City
2025-09-11
Recruiting
A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-1)
NCT07011732Alzheimer Disease
DrugsKarX-EC·KarXT
Bristol-Myers Squibb
Phase 3
426
Saltillo, Guadalajara, Mexico City, Monterrey, San Luis Potosí City, Tlalnepantla
2025-07-10
Active, closed
A Study to Compare Iberdomide Maintenance Versus Lenalidomide Maintenance Therapy Following Autologous Stem Cell Transplant in Participants With Newly Diagnosed Multiple Myeloma
NCT05827016Multiple Myeloma
DrugsIberdomide·Lenalidomide
Bristol-Myers Squibb
Phase 3
1,230
Monterrey, Toluca
2023-06-22
Active, closed
A Study to Evaluate Effectiveness and Safety of Deucravacitinib (BMS-986165) Compared With Placebo in Participants With Active Systemic Lupus Erythematosus
NCT05620407Systemic Lupus Erythematosus
DrugDeucravacitinib
Bristol-Myers Squibb
Phase 3
513
Torreón, León, Guadajalara, Zapopan, Mexico City, Cuernavaca, Monterrey, Chihuahua City
2023-01-12
Active, closed
A Study to Evaluate Efficacy and Safety of Deucravacitinib in Participants With Active Discoid and/or Subacute Cutaneous Lupus Erythematosus (DLE/SCLE)
NCT04857034Lupus Erythematosus, Discoid, Lupus Erythematosus, Subacute Cutaneous
DrugDeucravacitinib
Bristol-Myers Squibb
Phase 2
74
Guadalajara, Zapopan, Monterrey, Aguascalientes, Mexico City
2021-07-12
Active, closed
A Study of Subcutaneous Nivolumab Versus Intravenous Nivolumab in Participants With Previously Treated Clear Cell Renal Cell Carcinoma That is Advanced or Has Spread
NCT04810078Clear Cell Renal Cell Carcinoma
DrugsNivolumab and rHuPH20·Opdivo·Nivolumab
Bristol-Myers Squibb
Phase 3
681
Torreón, Tlalpan, Monterrey, Querétaro City, San Luis Potosí City
2021-05-21
Active, closed
A Study of Neoadjuvant Chemotherapy Plus Nivolumab Versus Neoadjuvant Chemotherapy Plus Placebo, Followed by Surgical Removal and Adjuvant Treatment With Nivolumab or Placebo for Participants With Surgically Removable Early Stage Non-small Cell Lung Cancer
NCT04025879Carcinoma, Non-Small-Cell Lung
DrugsOpdivo·Pemetrexed·Docetaxel·Nivolumab
Bristol-Myers Squibb
Phase 3
461
Chihuahua City, Guadalajara, Monterrey
2019-11-05
Recruiting
Pan Tumor Rollover Study
NCT03899155Cancer
DrugsRucaparib·Sunitinib·Relatlimab·Trametinib
Bristol-Myers Squibb
Phase 2
1,500
León, Zapopan, Cuauhtémoc, Tlalpan, Morelia, Monterrey, Oaxaca City, Querétaro City
2019-08-09
Active, closed
A Study of Nivolumab Combined With Ipilimumab Versus Nivolumab Alone in Participants With Advanced Kidney Cancer
NCT03873402Renal Cell Carcinoma
DrugsYervoy·Opdivo·Ipilimumab·Nivolumab
Bristol-Myers Squibb
Phase 3
437
Mexico City, Monterrey, Chihuahua City, Querétaro
2019-06-21
Active, closed
A Study of Nivolumab in Participants With Hepatocellular Carcinoma Who Are at High Risk of Recurrence After Curative Hepatic Resection or Ablation
NCT03383458Hepatocellular Carcinoma, Liver Cancer
DrugsOpdivo·Nivolumab
Bristol-Myers Squibb
Phase 3
545
Cuauhtémoc, Monterrey, San Luis Potosí City
2018-04-18
Active, closed
A Study of Relatlimab Plus Nivolumab Versus Nivolumab Alone in Participants With Advanced Melanoma
NCT03470922Melanoma
DrugsRelatlimab·Nivolumab
Bristol-Myers Squibb
Phase 2/3
714
Zapopan, Monterrey, Cancún, Mérida, Veracruz
2018-04-11
Active, closed
Study of Nivolumab in Combination With Ipilimumab or Standard of Care Chemotherapy Compared to the Standard of Care Chemotherapy Alone in Treatment of Participants With Untreated Inoperable or Metastatic Urothelial Cancer
NCT03036098Urothelial Cancer
DrugsYervoy·Opdivo·Ipilimumab·Nivolumab
Bristol-Myers Squibb
Phase 3
1,314
Mexico City, Tlalpan, Monterrey
2017-03-24
Rows per page Showing 1–21 of 21
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Mexican investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 2 October 2026. https://priyalifescience.com/clinical-trials-mexico/city/monterrey

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in Mexico and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 1,580 studies in total at the last sync on 30 Sep 2026, 03:17 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 21 of those studies with a site in Monterrey that also match the filters currently applied.

How many clinical trials are recruiting in Monterrey?

10 of the 21 studies on this page are recruiting new participants as of the 30 Sep 2026, 03:17 UTC sync. A further 1 have not yet opened recruitment, 10 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Monterrey), 21 studies
PhaseStudiesRecruitingShare
Phase 314666.7%
Phase 2/34219%
Phase 2219.5%
Phase 1/2114.8%

Most active sponsors

Lead sponsors with the most studies (Monterrey)
Lead sponsorStudiesRecruiting
Bristol-Myers Squibb2110
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.